WO1997039000A1 - Thieno-pyridine sulfonamides, derivatives thereof and related compounds that modulate the activity of endothelin - Google Patents
Thieno-pyridine sulfonamides, derivatives thereof and related compounds that modulate the activity of endothelin Download PDFInfo
- Publication number
- WO1997039000A1 WO1997039000A1 PCT/US1997/005994 US9705994W WO9739000A1 WO 1997039000 A1 WO1997039000 A1 WO 1997039000A1 US 9705994 W US9705994 W US 9705994W WO 9739000 A1 WO9739000 A1 WO 9739000A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- endothelin
- alkyl
- methyl
- compound
- aryl
- Prior art date
Links
- 0 CC(C1(*)C=NN=CC1)=C Chemical compound CC(C1(*)C=NN=CC1)=C 0.000 description 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to the compounds that modulate the activity of the endothelin family of peptides.
- the invention relates to the use of sulfonamides and sulfonamide pro-drugs as endothelin agonists and antagonists.
- the vascular endothelium releases a variety of vasoactive substances, including the endothelium-derived vasoconstrictor peptide, endothelin (ET) (see, e.g., Vanhoutte et aL (1986) Annual Rev. Physiol. 48: 307-320; Furchgott and Zawadski ( 1 980) Nature 288: 373-376) .
- Endothelin which was originally identified in the culture supernatant of porcine aortic endothelial cells (see, Yanagisawa et aL ( 1 988) Nature 332: 41 1 -41 5), is a potent twenty-one amino acid peptide vasoconstrictor.
- Endothelin is synthesized as a two hundred and three amino acid precursor preproendothelin that contains a signal sequence which is cleaved by an endogenous protease to produce a thirty-eight (human) or thirty-nine (porcine) amino acid peptide.
- This intermediate referred to as big endothelin, is processed in vivo to the mature biologically active form by a putative endothelin-converting enzyme (ECE) that appears to be a metal-dependent neutral protease (see, e.g.
- the family of three isopeptides, endothelin- 1 , endothelin-2 and endothelin-3 are encoded by a family of three genes (see, Inoue et aL. ( 1 989) Proc. Natl. Acad. Sci. USA 86: 2863-2867; see, also Saida et aL ( 1 989U. Biol. Chem. 264: 1461 3-1461 6) .
- the nucleotide sequences of the three human genes are highly conserved within the region encoding the mature 21 amino acid peptides and the C-terminal portions of the peptides are identical.
- Endothelin-2 is (Trp 6 ,Leu 7 ) endothelin-1 and endothelin-3 is (Thr 2 ,Phe 4 ,Thr 5 ,Tyr 6 ,Lys 7 ,Tyr 14 ) endothelin- 1 .
- These peptides are, thus, highly conserved at the C-terminal ends.
- endothelins from cultured endothelial cells is modulated by a variety of chemical and physical stimuli and appears to be regulated at the level of transcription and/or translation.
- Expression of the gene encoding endothelin-1 is increased by chemical stimuli, including adrenaline, thrombin and Ca 2 + ionophore.
- the production and release of endothelin from the endothelium is stimulated by angiotensin II, vasopressin, endotoxin, cyclosporine and other factors (see, Brooks et al. ( 1 991 ) Eur. J. Pharm. 194: 1 1 5- 1 17), and is inhibited by nitric oxide.
- Endothelial cells appear to secrete short-lived endothelium-derived relaxing factors (EDRF) , including nitric oxide or a related substance (Palmer et aL ( 1 987) Nature 327: 524-526), when stimulated by vaso ⁇ active agents, such as acetylcholine and bradykinin. Endothelin-induced vasoconstriction is also attenuated by atrial natriuretic peptide (ANP). The endothelin peptides exhibit numerous biological activities in vitro and m vivo.
- EDRF endothelium-derived relaxing factors
- Endothelin provokes a strong and sustained vasoconstriction in_ vivo in rats and in isolated vascular smooth muscle preparations; it also provokes the release of eicosanoids and endothelium-derived relaxing factor (EDRF) from perfused vascular beds.
- EDRF endothelium-derived relaxing factor
- Intravenous administration of endothelin-1 and in vitro addition to vascular and other smooth muscle tissues produce long-lasting pressor effects and contraction, respectively (see, e.g., Bolger et aL ( 1 991 ) Can. J. Physiol. Pharmacol. 69: 406-41 3).
- Endothelin also mediates renin release, stimulates ANP release and induces a positive inotropic action in guinea pig atria.
- endothelin- 1 acts as a potent bronchoconstrictor (Maggi et aL ( 1 989) Eur. J. Pharmacol. 160: 179-182).
- Endothelin increases renal vascular resistance, decreases renal blood flow, and decreases glomerular filtrate rate. It is a potent mitogen for glomerular mesangial cells and invokes the phosphoinoside cascade in such cells (Simonson et aL ( 1 990) J. Clin. Invest. 85: 790-797).
- binding sites There are specific high affinity binding sites (dissociation constants in the range of 2-6 x 10 "10 M) for the endothelins in the vascular system and in other tissues, including the intestine, heart, lungs, kidneys, spleen, adrenal glands and brain. Binding is not inhibited by catecholamines, vasoactive peptides, neurotoxins or calcium channel antagonists. Endothelin binds and interacts with receptor sites that are distinct from other autonomic receptors and voltage dependent calcium channels. Competitive binding studies indicate that there are multiple classes of receptors with different affinities for the endothelin isopeptides.
- the sarafotoxins a group of peptide toxins from the venom of the snake Atractaspis eingadensis that cause severe coronary vasospasm in snake bite victims, have structural and functional homology to endothelin-1 and bind competitively to the same cardiac membrane receptors (Kloog et al. ( 1 989) Trends Pharmacol. Sci. 10: 21 2-214).
- ET A and ET B Two distinct endothelin receptors, designated ET A and ET B , have been identified and DNA clones encoding each receptor have been isolated (Arai et aL ( 1 990) Nature 348: 730-732; Sakurai et aJL ( 1 990) Nature 348: 732-735) . Based on the amino acid sequences of the proteins encoded by the cloned DNA, it appears that each receptor contains seven membrane spanning domains and exhibits structural similarity to G-protein-coupled membrane proteins. Messenger encoding both receptors has been detected in a variety of tissues, including heart, lung, kidney and brain. The distribution of receptor subtypes is tissue specific (Martin et aL ( 1 989) Biochem. Biophys. Res.
- ET A receptors appear to be selective for endothelin-1 and are predominant in cardiovascular tissues.
- ET B receptors are predominant in noncardiovascular tissues, including the central nervous system and kidney, and interact with the three endothelin isopeptides (Sakurai et aL ( 1 990) Nature 348: 732-734).
- ET A receptors occur on vascular smooth muscle, are linked to vasoconstriction and have been associated with cardiovascular, renal and central nervous system diseases; whereas ET B receptors are located on the vascular endothelium, are linked to vasodilation (Takayanagi et al. ( 1 991 ) FEBS Lttrs. 282: 103-106) and have been associated with bronchoconstrictive disorders.
- the activity of the en ⁇ dothelin isopeptides varies in different tissues.
- endothelin-1 inhibits 125 l-labelled endothelin-1 binding in cardiovascular tissues forty to seven hundred times more potently than endothelin-3.
- 125 l-labelled endo ⁇ thelin-1 binding in non-cardiovascular tissues, such as kidney, adrenal gland, and cerebellum is inhibited to the same extent by endothelin-1 and endothelin-3, which indicates that ET A receptors predominate in cardiovascular tissues and ET B receptors predominate in non- cardiovascular tissues.
- Endothelin plasma levels are elevated in certain disease states (see, e g.., International PCT Application WO 94/27979, and U.S. Patent No. 5,382,569, which disclosures are herein incorporated in their entirety by reference).
- Endothelin- 1 plasma levels in healthy individuals as measured by radioimmunoassay (RIA), are about 0.26-5 pg/ml.
- Blood levels of endothelin- 1 and its precursor, big endothelin are elevated in shock, myocardial infarction, vasospastic angina, kidney failure and a variety of connective tissue disorders.
- Circulating and tissue endothelin immunoreactivity is increased more than twofold in patients with advanced atherosclerosis (Lerman et aL (1 991 ) New Engl. J. Med. 325:997-1001 ). Increased endothelin immunoreactivity has also been associated with Buerger's disease (Kanno et aL ( 1 990) J. Amer. Med. Assoc. 264:2868) and Raynaud's phenomenon (Zamora et al. ( 1 990) Lancet 336 1 144-1 T47). Increased circulating endothelin levels were observed in patients who underwent percutaneous transluminal coronary angioplasty (PTCA) (Tahara et aL ( 1991 ) Metab. Clin. Exp.
- PTCA percutaneous transluminal coronary angioplasty
- endothelin is associated with certain disease states and is implicated in numerous physiological effects
- compounds that can interfere with or potentiate endothelin-associated activities such as endothelin-receptor interaction and vasoconstrictor activity, are of interest.
- Compounds that exhibit endothelin antagonistic activity have been identified.
- a fermentation product of Streptomyces misakiensis designated BE- 1 8257B, has been identified as an ET A receptor antagonist.
- BE-18257B is a cyclic pentapeptide, cyclo(D-Glu-L- Ala-allo-D-lle-L-Leu-D-Trp), which inhibits 125 l-labelled endothelin-1 binding in cardiovascular tissues in a concentration-dependent manner (IC 50 1.4 ⁇ M in aortic smooth muscle, 0.8 ⁇ M in ventricle membranes and 0.5 ⁇ M in cultured aortic smooth muscle cells), but fails to inhibit binding to receptors in tissues in which ET B receptors predominate at concentrations up to 100 ⁇ M.
- Cyclic pentapeptides related to BE- 18257B such as cyclo(D-Asp-Pro-D-Val-Leu-D-Trp) (BQ-123), have been synthesized and shown to exhibit activity as ET A receptor antagonists (see, U.S. Patent No.5,114,918 to Ishikawa et aJL; see, also, EP A1 0 436189 to BANYU PHARMACEUTICAL CO., LTD (October 7, 1991)).
- Studies that measure the inhibition by these cyclic peptides of endothelin-1 binding to endothelin-specific receptors indicate that these cyclic peptides bind preferentially to ET A receptors.
- Patent No.5,114,918 to Ishikawa et aL EP A1 0 569193; EP A1 0558258; EP A1 0436189 to BANYU PHARMACEU- TICAL CO., LTD (October 7, 1991); Canadian Patent Application
- the identified compounds have activities in in vitro assays as ET A antagonists at concentrations on the order of about 50- 100 ⁇ M or less. A number of such compounds have also been shown to possess activity in in vivo animal models. Very few, if any, selective ET B antagonists have been identified. Endothelin antagonists and agonists as therapeutic agents
- such compounds are considered to be useful for the treatment of hypertension such as peripheral circulatory failure, heart disease such as angina pectoris, cardiomyopathy, arteriosclerosis, myocardial infarction, pulmonary hypertension, vasospasm, vascular restenosis, Raynaud's disease, cerebral stroke such as cerebral arterial spasm, cerebral ischemia, late phase cerebral spasm after subarachnoid hemorrhage, asthma, bronchoconstriction, renal failure, particularly post-ischemic renal failure, cyclosporine nephrotoxicity such as acute renal failure, colitis, as well as other inflammatory diseases, endotoxic shock caused by or associated with endothelin, and other diseases in which endothelin has been implicated.
- hypertension such as peripheral circulatory failure
- heart disease such as angina pectoris, cardiomyopathy, arteriosclerosis, myocardial infarction
- pulmonary hypertension such as cerebral arterial spasm, cerebral ischemia, late phase cerebral spasm after subarachnoid hemor
- endothelin is believed to play a critical role in these pathophysiological conditions (see, e.g. , Saito et aL ( 1 990) Hypertension 15: 734-738; Tomita et aL ( 1 989) N. Engl. J. Med. 321 : 1 1 27; Kurihara et aL ( 1 989) J. Cardiovasc. Pharmacol. 1 3(Suppl. 5): S1 3-S1 7; Doherty ( 1 992) J. Med. Chem. 35: 1493-1 508; Morel et aL ( 1 989) Eur. J. Pharmacol. 167: 427-428) . More detailed knowledge of the function and structure of the endothelin peptide family should provide insight in the progression and treatment of such conditions.
- Sulfonamides and methods for modulating the interaction of an endothelin peptide with ET A and/or ET B receptors are provided.
- sulfonamides and methods for inhibiting the binding of an endothelin peptide to ET A or ET B receptors are provided.
- the methods are effected by contacting the receptors with one or more sulfonamides prior to, simultaneously with, or subsequent to contacting the receptors with an endothelin peptide.
- the sulfonamides are substituted or unsubstituted monocyclic or polycyclic aromatic or heteroaromatic sul- fonamides.
- Particularly preferred sulfonamides are N-isoxazolyl sulfona ⁇ mides.
- the sulfonamides have formula I: Ar— SO r N- Ar 1
- Ar 1 is a substituted or unsubstituted aryl group with one or more substituents, including an alkyl group, an aryl group, a nitro group, an amino group, or a halide, or is an alkyl group.
- Ar 1 is alkyl or is a five or six membered substituted or unsubstituted aromatic or heteroaromatic ring, particularly 3- or 5- isoxazolyl and pyridazinyl, and also including thiazolyl, including 2-thiazolyl, pyrimidyl, including 2- pyrimidyl, or substituted benzene groups, including aryloxy substituted benzene groups, or is a bicyclic or tricyclic carbon or heterocyclic ring.
- Ar 1 is, in certain embodiments, selected from groups such as:
- R is selected from H, NH 2 , halide, pseudohalide, alkyl, alkylcarbonyl, formyl, an aromatic or heteroaromatic group, alkoxyalkyl, alkylamino, alkylthio, arylcarbonyl, aryloxy, arylamino, arylthio, haloalkyl, haloaryl, carbonyl, in which the aryl and alkyl portions are unsubstituted or substituted with any of the preceding groups, and are straight or branched chains of from about 1 up to about 10-1 2 carbons, preferably 1 to about 5 or 6 carbons.
- R is preferably H, NH 2 , halide, CH 3 , CH 3 O or another aromatic group.
- Ar 2 is any group such that the resulting sulfonamide inhibits binding by 50%, compared to binding in the absence of the sulfonamide, of an endothelin peptide to an endothelin receptor at a concentration of less than about 1 00 ⁇ M, except that Ar 2 is not phenyl or naphthyl when Ar 1 is N-(5-isoxazolyl) or N-(3-isoxazolyl) unless the isoxazole is a 4-halo- isoxazole, a 4-higher alkyl (C 8 to C 15 )-isoxazole, or the compound is a 4- biphenyl that is unsubstituted at the 2 or 5 position on the sulfonamide- linked phenyl group.
- Ar 2 is a heterocycle that contains one ring, multiple rings or fused rings, typically two or three rings and one or two heteroatoms in the ring or rings.
- Ar 2 is a substituted or unsubstituted group selected from among groups including, but not limited to, the following: naphthyl, phenyl, biphenyl, quinolyl, styryl, thienyl, furyl, isoquinolyl, pyrrolyl, benzofuranyl, pyridyl, thionaphthalyl, indolyl, alkyl, alkenyl, and other single and fused ring heterocyclic groups.
- Ar 2 is a single ring heterocycle, particularly a 5-membered ring, or is a fused bicyclic or tricyclic heterocycle that contains one or or more, particularly one, heteroatom selected from S, O, N and NR 11 , in the ring, where R 11 contains up to about 30 carbon atoms, preferably 1 to 10, more preferably 1 to 6 and is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocycle, aralkyl, aralkoxy, cycioalkyl, cycloalkenyl, cycloalkynyl, C(O)R 15 and S(O) n R 15 in which n is 0-2; R 15 is hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocycle, aralkyl, aralkoxy, cycioalkyl, cycloalken
- R 1 1 is aryl, such as phenyl or alkyl phenyl, or is hydrogen or lower alkyl.
- Ar 2 is a fused ring bicyclic heterocyle and Ar 1 is preferably a five or 6-membered heterocyclic ring.
- Ar 1 is preferably an isoxazole and Ar 2 is preferably a fused ring bicyclic heterocycle containing one heteroatom in each ring and containing 5 or 6 members in each ring.
- Ar 2 is selected from among fused bicyclic heteroaryl groups, such as those having formula:
- Y is N or O + , preferably N;
- X is S, O, NR 1 1 , where R 1 1 is as defined above;
- R 3 , R 4 and R 5 are selected from (i), (ii), (iii) or (iv): (i) R 3 , R 4 and R 5 are each selected independently from among H, NHOH, NH 2 , NO 2 , N 3 , halide, pseudohalide, alkyl, alkenyl, alkynyl, alkylaryl, aryloxy, aryl, heteroaryl, alkoxy, alkylamino, alkylthio, alkoxyalkyl, alkylsulfinyl, alkylsulfonyl, arylamino, arylthio, arylsulfinyl, arylsulfonyl, haloalkyl, haloaryl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, formyl or amido, where the alkyl, alkenyl, alkynyl portions are straight or branched chains of from about 1 up to
- R 3 , R 4 and R 5 are independently selected from alkyl, alkoxy, halide, aminoalkyl, dialkylaminoalkyl, in which the alkyl and alkoxy groups contain from 1 to 10, preferably 1 to 6 carbons, and are straight or branched chains and the other is H; or
- R 3 , R 4 and R 5 which are each selected as in (i) form fused carbocyclic or heterocyclic rings; and R 7 is hydrogen or contains up to about 50 carbon atoms, generally up to about 30, more generally 20 or fewer, and is selected hydrogen, halide, pseudohalide, alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, heterocycle, aralkyl, aralkoxy, cycioalkyl, cycloalkenyl, cycloalkynyl, OH, CN, SH, S(O) n , (CH 2 ) r R 1 B , C(O)R 18 , CO 2 R 18 , (CH 2 ) r COR 18 , OR 18 , (CH 2 ) r CO(CH 2 ) s R 18 , S(O) n R 18 in which n is 0-2, and r and s are each independently 0
- R 1 1 is as defined above, and is preferably hydrogen or aryl, more preferably hydrogen or phenyl; and R 1 and R 2 are either (i), (ii) or (iii) as follows:
- R 1 and R 2 are each independently selected from H, NH 2 , NO 2 , halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, alkyloxy, haloalkyl, alkylsufinyl, alkylsulfonyl, aryloxy, arylamino, arylthio, arylsufinyl, arylsulfonyl, haloaryl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, arylcarbonyl, formyl, substituted or unsubstituted amido, substituted or unsubstituted ureido, in which the alkyl, alkenyl and alkynyl portions contain from 1 up to about 14 carbon atoms and are either straight or branched chains or cyclic, and the alky
- R 7 is (CH 2 ) r R 18 , where R 18 is aryl, preferably phenyl or pyrimidyl, more preferably phenyl, which is unsubstituted or substited with alkyl, haloalkyl, halide, or such that two adjacent positions are substituted and together form alkylenedioxy, particularly methylenedioxy and ethylenedioxy.
- R 1 and R 2 are each selected independently from among alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, halide, pseudohalide or H, except that R 2 is not halide.
- the alkyl, alkynyl and alkenyl portions of each listed substituent are straight or branched chains, acyclic or cyclic, and preferably have from about 1 up to about 10 carbons; in more preferred embodiments they have from 1 -6 carbons.
- the aryl, alicyclic, aromatic rings and heterocyclic groups can have from 3 to 1 6, generally, 3-7, more often 5-7 members in the rings, and may be single or fused rings.
- the ring size and carbon chain length are selected up to an amount that the resulting molecule binds and retains activity as an endothelin antagonist or agonist, such that the resulting compound inhibits binding by 50%, compared to binding in the absence of the sulfonamide, of an endothelin peptide to an endothelin receptor at a concentration of less than about 100 ⁇ M.
- R 2 is preferably selected from among alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, or H; and R 1 is halide or lower alkyl, and more preferably, R 1 is bromide or chloride, methyl or ethyl and R 2 is methyl, ethyl or haloalkyl, particularly CF 3 .
- R 1 is bromide or chloride.
- R 18 is C(O)R 27 in which R 27 is aryl, and is preferably (CH 2 ) r C(O)(CH 2 ) p -aryl, (CH 2 ) r C(O)aryl, (CH 2 ) r S(O) q (CH 2 ) p - aryl, C(O)NR 1 l -aryl, NHC(O)(CH 2 ) r -aryl, NR 1 1 -aryl, (CH 2 ) r aryl in which p and r are each independently selected from 0-10, preferably 0-6, more preferably 0-3, most preferably 0 or 1 and q is 0-3, preferably 0-2.
- the aryl portion is unsubstituted or is substituted with groups such as alkyl, alkoxy, alkoxyalkyl, halogen, alkylenedioxy, particularly methylenedioxy, N-alkyl, N-alkyoxy, amino, nitro and other such groups.
- the alkyl substituents are preferably lower alkyl, more preferably containing 1 -3 carbons.
- IC 50 concentration determined in the in vitro assays is a non-linear function of incubation temperature.
- the preferred values recited herein refer to the assays that are performed at 4° C. When the assays are performed at 24° C, somewhat higher (see, Table 1 ) IC 50 concentrations are observed. Accordingly, the preferred IC 50 concentrations are about 10-fold higher.
- ET A selective, Le ⁇ they interact with ET A receptors at substantially lower concentrations (at an IC 50 at least about 10-fold lower, preferably 100-fold lower) than they interact with ET B receptors.
- Preferred compounds also include compounds that are ET B receptor selective or that bind to ET B receptors with an IC 50 of less than about 1 ⁇ M.
- ET B selective compounds interact with ET B receptors at IC 50 concentrations that are at least about 10-fold lower than the concentrations at which they interact with ET A receptors.
- R 2 is selected from among alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, halide or H; and R 1 is halide or lower alkyl, and in preferred embodiments, R 1 is bromide or chloride.
- Particularly preferred compositions are those that deliver amounts effective for the treatment of hypertension or renal failure.
- the effective amounts and concentrations are effective for ameliorating any of the symptoms of any of the disorders.
- Methods for inhibiting binding of an endothelin peptide to an endothelin receptor are provided. These methods are practiced by contacting the receptor with one or more of the compounds provided herein simultaneously, prior to, or subsequent to contacting the receptor with an endothelin peptide.
- Methods for treatment of endothelin-mediated disorders including but not limited to, hypertension, asthma, shock, ocular hypertension, glaucoma, inadequate retinal perfusion and other conditions that are in some manner mediated by an endothelin peptide, or for treatment of disorders that involve vasoconstriction or that are ameliorated by administration of an endothelin antagonist or agonist are provided.
- methods of treating endothelin-mediated disorders by administering effective amounts of the sulfonamides, prodrugs or other suitable derivatives of the sulfonamides are provided.
- methods for treating endothelin-mediated disorders including hypertension, cardiovascular diseases, cardiac diseases including myocardial infarction, pulmonary hypertension, erythropoietin-mediated hypertension, respiratory diseases and inflammatory diseases, including asthma, bronchoconstriction, ophthalmologic diseases, gastroenteric diseases, renal failure, endotoxin shock, menstrual disorders, obstetric conditions, wounds, anaphylactic shock, hemorrhagic shock, and other diseases in which endothelin mediated physiological responses are implicated, by administering effective amounts of one or more of the compounds provided herein in pharmaceutically acceptable carriers are provided.
- Preferred methods of treatment are methods for treatment of hypertension and renal failure.
- compositions contain at least one compound that inhibits the interaction of endothelin- 1 with ET A receptors at an IC 50 of less than about 10 ⁇ M, and preferably less than about 5 ⁇ M, more preferably less than about 1 ⁇ M, even more preferably less than 0.1 ⁇ M, and most preferably less than 0.05 ⁇ M.
- Other preferred methods are those in which the compositions contain one or more compounds that is (are) ET A selective or one or more compounds that is (are) ET B selective. Methods in which the compounds are ET A selective are for treatment of disorders, such as hypertension; and methods in which the compounds are ET B selective are for treatment of disorders, such as asthma, that require bronchodilation.
- compositions containing therapeutically effective concentrations of the compounds formulated for oral, intravenous, local and topical application for the treatment of hypertension, cardiovascular diseases, cardiac diseases, including myocardial infarction, respiratory diseases, including asthma, inflammatory diseases, ophthalmologic diseases, gastroenteric diseases, renal failure, immunosuppressant-mediated renal vasoconstriction, erythropoietin-mediated vasoconstriction, endotoxin shock, anaphylactic shock, hemorrhagic shock, pulmonary hypertension, and other diseases in which endothelin mediated physiological responses are implicated are administered to an individual exhibiting the symptoms of one or more of these disorders.
- the amounts are effective to ameliorate or eliminate one or more symptoms of the disorders.
- Methods for the identification and isolation of endothelin receptor subtypes are also provided.
- methods for detecting, distinguishing and isolating endothelin receptors using the disclosed compounds are provided.
- endothelin (ET) peptides include peptides that have substantially the amino acid sequence of endothelin- 1 , endothelin-2 or endothelin-3 and that act as potent endogenous vasoconstrictor peptides.
- an endothelin-mediated condition is a condition that is caused by abnormal endothelin activity or one in which compounds that inhibit endothelin activity have therapeutic use.
- diseases include, but are not limited to hypertension, cardiovascular disease, asthma, inflammatory diseases, ophthalmologic disease, menstrual disorders, obstetric conditions, gastroenteric disease, renal failure, pulmonary hypertension, endotoxin shock, anaphylactic shock, or hemorrhagic shock.
- Endothelin-mediated conditions also include conditions that result from therapy with agents, such as erythropoietin and immunosuppressants, that elevate endothelin levels.
- an effective amount of a compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce the symptoms associated with the disease. Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective. The amount may cure the disease but, typically, is administered in order to ameliorate the symptoms of the disease. Typically, repeated administration is required to achieve the desired amelioration of symptoms.
- an endothelin agonist is a compound that potentiates or exhibits a biological activity associated with or possessed by an endothelin peptide.
- an endothelin antagonist is a compound, such as a drug or an antibody, that inhibits endothelin-stimulated vasoconstriction and contraction and other endothelin-mediated physiological responses.
- the antagonist may act by interfering with the interaction of the endothelin with an endothelin-specific receptor or by interfering with the physiological response to or bioactivity of an endothelin isopeptide, such as vasoconstriction.
- an endothelin antagonist interferes with endothelin-stimulated vasoconstriction or other response or interferes with the interaction of an endothelin with an endothelin-specific receptor, such as ET A receptors, as assessed by assays known to those of skill in the art.
- endothelin agonist activity can be identified by its ability to stimulate vasoconstriction of isolated rat thoracic aorta or portal vein ring segments (Borges et aL ( 1 989) "Tissue selectivity of endothelin” Eur. J. Pharmacol. 1 65: 223-230) .
- Endothelin antagonist activity can be assessed by the ability to interfere with endothelin-induced vasoconstriction. Exemplary assays are set forth in the EXAMPLES.
- the preferred IC 50 concentration ranges are set forth with reference to assays in which the test compound is incubated with the ET receptor-bearing cells at 4° C. Data presented for assays in which the incubation step is performed at the less preferred 24° C are identified. It is understood that for purposes of comparison, these concentrations are somewhat higher than the concentrations determined at 4° C.
- the biological activity or bioactivity of endothelin includes any activity induced, potentiated or influenced by endothelin in vivo. It also includes the ability to bind to particular receptors and to induce a functional response, such as vasoconstriction. It may be assessed by in vivo assays or by in vitro assays, such as those exemplified herein.
- the relevant activities include, but are not limited to, vasoconstriction, vasorelaxation and bronchodilation.
- ET B receptors appear to be expressed in vascular endothelial cells and may mediate vasodilation and other such responses; whereas ET A receptors, which are endothelin- 1 -specific, occur on smooth muscle and are linked to vasoconstriction Any assay known to those of skill in the art to measure or detect such activity may be used to assess such activity (see, e.g.. Spokes et al. ( 1 989) J. Cardiovasc. Pharmacol. 13(Suppl. 51S191 -S192; Spinella et aL ( 1 991 ) Proc. Natl. Acad. Sci. USA 88: 7443-7446; Cardell et al. ( 1 991 ) Neurochem. Int. 18:571 -574) : and the Examples herein).
- the IC 50 refers to an amount, concentration or dosage of a particular test compound that achieves a 50% inhibition of a maximal response, such as binding of endothelin to tissue receptors, in an assay that measures such response.
- EC 50 refers to a dosage, concentration or amount of a particular test compound that elicits a dose-dependent response at 50% of maximal expression of a particular response that is induced, provoked or potentiated by the particular test compound.
- a sulfonamide that is ET A selective refers to sulfon ⁇ amides that exhibit an IC 50 that is at least about 10-fold lower with respect to ET A receptors than ET B receptors.
- a sulfonamide that is ET B selective refers to sulfon ⁇ amides that exhibit an IC 50 that is at least about 10-fold lower with respect to ET B receptors than ET A receptors.
- pharmaceutically acceptable salts, esters or other derivatives of the compounds include any salts, esters or derivatives that may be readily prepared by those of skill in this art using known methods for such derivatization and that produce compounds that may be administered to animals or humans without substantial toxic effects and that either are pharmaceutically active or are prodrugs.
- hydroxy groups can be esterified or etherified.
- treatment means any manner in which the symptoms of a conditions, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use as contraceptive agents.
- amelioration of the symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.
- substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance.
- TLC thin layer chromatography
- HPLC high performance liquid chromatography
- Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art.
- a substantially chemically pure compound may, however, be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound.
- biological activity refers to the in vivo activities of a compound or physiological responses that result upon in vivo administration of a compound, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures.
- a prodrug is a compound that, upon in vivo administration, is metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound.
- the pharmaceutically active compound is modified such that the active compound will be regenerated by metabolic processes.
- the prodrug may be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or pro ⁇ perties of a drug.
- pseudohalides are compounds that behave substantially similar to halides. Such compounds can be used in the same manner and treated in the same manner as halides (X , in which X is a halogen, such as Cl or Br) .
- Pseudohalides include, but are not limited to cyanide, cyanate, thiocyanate, selenocyanate and azide.
- lower alkyl, lower alkenyl, and lower alkynyl refer to carbon chains having less than about 6 carbons.
- alkyl, alkenyl, or alkynyl portions include lower alkyl, lower alkenyl, and lower alkynyl portions.
- aryl refers to cyclic groups containing from 3 to 1 5 or 1 6 carbon atoms, preferably from 5 to 10.
- Aryl groups include, but are not limited to groups, such as phenyl, substituted phenyl, napthyl, substituted naphthyl, in which the substituent is lower alkyl, halogen, or lower alkoxy.
- Preferred aryl groups are lower aryl groups that contain less than 7 carbons in the ring structure.
- alkyl refers to saturated carbon chains that contain one or more carbons; the chains may be straight or branched or include cyclic portions or be cyclic.
- alicyclic refers to aryl groups that are cyclic.
- haloalkyl refers to a lower alkyl radical in which one or more of the hydrogen atoms are replaced by halogen including, but not limited to, chloromethyl, trifluoromethyl, 1 -chloro-2-fluoroethyl and the like.
- haloalkoxy refers to RO- in which R is a haloalkyl group.
- aminocarbonyl refers to -C(O)NH 2 .
- alkylaminocarbonyl refers to -C(O)NHR in which R is hydrogen, alkyl, preferably lower alkyl or aryl, preferably lower aryl.
- dialkylaminocarbonyl refers to -C(O)NR R in which R and R are independently selected from alkyl or aryl, preferably lower alkyl or lower aryl;
- carboxamide refers to groups of formula NR ' COR.
- alkoxycarbonyl refers to -C(O)OR in which R is alkyl, preferably lower alkyl or aryl, preferably lower aryl.
- alkoxy and thioalkoxy refer to RO- and RS-, in which R is alkyl, preferably lower alkyl or aryl, preferably lower aryl.
- cycioalkyl refers to saturated cyclic carbon chains
- cycloalkenyl and cycloalkynyl refer to cyclic carbon chains that include at least one unsaturated double or triple bond.
- the cyclic portions of the carbon chains may include one ring or two or more fused rings.
- heterocycle or heteroaryl refers to ring structures that include at least one carbon atom and one or more atoms, such as N, S and O.
- the rings may be single rings or two or more fused rings.
- Heteroaryl is used interchangeably with heterocycle.
- any corresponding N-(4-halo-3-methyl-5-isox- azolyl), N-(4-halo-5-methyl-3-isoxazolyl), N-(3,4-dimethyl-5-isoxazolyl), N- (4,5-dimethyl-3-isoxazolyl) derivative thereof refers to compounds in which Ar 2 is the same as the compound specifically set forth, but Ar 1 is N-(4-halo-3-methyl-5-isoxazolyl), N-(4-halo-5-methyl-3-isoxazolyl), N-(3,4- dimethyl-5-isoxazolyl), or N-(4,5-dimethyl-3-isoxazolyl) in which halo is any halide, preferably Cl or Br.
- Y is N or O + ;
- X is S, O, NR 1 1 , in which R 11 contains up to about 30 carbon atoms, preferably 1 to 1 0, more preferably 1 to 6 and is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocycle, aralkyl, aralkoxy, cycioalkyl, cycloalkenyl, cycloalkynyl, C(O)R 15 and S(O) n R 15 in which n is 0-2;
- R 15 is hydrogen, alkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocycle, aralkyl, aralkoxy, cycioalkyl, cycloalkenyl, cycloalkynyl;
- R 1 1 and R 15 are unsubstituted or are substituted with one or more substituents each selected independently from Z, which is hydrogen
- R 1 and R 2 together form -(CH 2 ) n , where n is 3 to 6; or, (iii) R 1 and R 2 together form 1 ,3-butadienyl;
- R 3 , R 4 and R 5 are selected from (i), (ii), (iii) or (iv) :
- R 3 , R 4 and R 5 are each selected independently from among H, NHOH, NH 2 , N0 2 , N 3 , halide, pseudohalide, alkyl, alkenyl, alkynyl, alkylaryl, aryloxy, aryl, heteroaryl, alkoxy, alkylamino, alkylthio, alkoxyalkyl, alkylsulfinyl, alkylsulfonyl, arylamino, arylthio, arylsulfinyl, arylsulfonyl, haloalkyl, haloaryl, al
- R 3 , R 4 and R 5 are substituted or unsubstituted 1 ,3-butadienyl, 4-dimethylamino-1 ,3 butadienyl, 1 -chloro- 1 ,3-butadienyl, 1 -aza- 1 ,3-butadienyl or 2-aza-1 ,3-butadienyl groups; and the others of R 3 , R 4 and R 5 are as defined in (i) above; or alternatively,
- R 4 is H; and R 3 and R 5 are each independently selected from alkyl, alkoxy, halide, aminoalkyl, dialkylaminoalkyl, in which the alkyl and alkoxy groups contain from 1 to 10, preferably 1 to 6 carbons, and are straight or branched chains; or
- R 3 , R 4 and R 5 which are each selected as in (i) form fused carbocyclic or heterocyclic rings; and R 7 is hydrogen or contains up to about 50 carbon atoms, generally up to about 30, more generally 20 or fewer, and is selected hydrogen, halide, pseudohalide, alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, heterocycle, aralkyl, aralkoxy, cycioalkyl, cycloalkenyl, cycloalkynyl, OH, CN, C(O)R 18 , CO 2 R 18 , (CH 2 ) r R 18 , (CH 2 ) r COR 18 (CH 2 ) r CO(CH 2 ) s R 18 , SH, S(O) n , (CH 2 ) r , S(O) n R 18 in which n is 0-2, and s and r are each independently
- R 7 is preferably C(O)R 18 , C0 2 R 18 , (CH 2 ) r R 18 , (CH 2 ) r COR 18 (CH 2 ) r CO(CH 2 ) s R 18 , NR 18 R 19 , OR 18 , R 19 NCOR 18 or CONR 19 R 18 .
- More preferred compounds are those of formula (II) that have formula (III):
- R 7 is C(O)R 18 , CO 2 R 18 , (CH 2 ) r R 18 , (CH 2 ) r C(O)CH 2 ) s R 18 , NR 18 R 19 , OR 18 , R 19 NCOR 18 and CONR 19 R 18 in which r is 0 to 6, preferably 1 -3,
- R 7 , R 18 or R 19 is aryl, particularly phenyl, or includes an aryl group, particularly phenyl:
- R 32 , R 33 , R 34 , R 35 and R 36 are each independently selected from (i), (ii) or (iii) as follows: (i) R 32 , R 33 , R 34 , R 35 , and R 36 are each independently selected from among H, NHR 38 , CONR 38 , N0 2 , halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, alkoxy, haloalkyl, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, alkylcarbonyl, alkenylthio, alkenylamino, alkenyloxy, alkenylsulfinyl, alkenylsulfonyl, aminocarbonyl, carb
- R 32 , R 33 , R 34 , R 35 and R 36 are substituting adjacent carbons on the ring and together form alkylenedioxy, alkylenethioxyoxy or alkylenedithioxy (i.e. — 0-(CH 2 ) n -O-, — S-(CH 2 ) n -O-,
- R 32 , R 33 , R 34 , R 35 and R 36 are selected as in fi); or
- R 32 , R 33 , R 34 , R 35 and R 36 are substituting adjacent carbons on the ring and together form alkylenedioxy, alkylenethioxyoxy or alkylenedithioxy (Le ⁇ — O-(CH 2 ) n -O-, - S-(CH 2 ) n -O-,
- n 1 to 4, preferably 1 or 2), which is unsubstituted or substituted by replacing one or more hydrogens with halide, lower alkyl, lower alkoxy or halo(lower)alkyl, and at least two of the others of R 33 , R 34 , R 35 , and R 36 are substituting adjacent carbons on the ring and together form alkylenedioxy, alkylenethioxyoxy or alkylenedithioxy (Le,.
- n 1 to 4, preferably 1 or 2), which is unsubstituted or substituted by replacing one or more hydrogens with halide, lower alkyl, lower alkoxy or halo(lower)alkyl, and the other of R 32 , R 33 , R 34 , R 35 and R 36 is selected as in (i).
- At least one, more preferably two, of R 32 , R 33 , R 34 , R 35 and R 36 is H and the others are selected from among (i), (ii) or (iii) as follows:
- R 32 , R 33 , R 34 , R 34 , R 35 and R 36 are substituting adjacent carbons and together form alkylenedioxy and the others of R 32 , R 33 , R 34 , R 35 and R 36 are selected as set forth in (i); or
- R 32 , R 33 , R 34 , R 35 and R 36 are substituting adjacent carbons and together form alkylenedioxy, and at least two of the others of R 32 , R 33 , R 34 , R 35 and R 36 are substituting adjacent carbons and together form alkylenedioxy, and the other of R 32 , R 33 , R 34 , R 35 and R 36 is H.
- R 32 and R 36 is not hydrogen.
- R 7 , R 18 or R 19 is pyrimidyl, it is substituted with one or more substitutents selected from (i) or (ii) (i) H, NHR 38 , CONR 38 , NO 2 , halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, alkoxy, haloalkyl, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, alkylcarbonyl, alkenylthio, alkenylamino, alkenyloxy, alkenylsulfinyl, alkenylsulfonyl, aminocarbonyl, carboxy, carboxyalkyl, carboxyalkenyl, and formyl, where R 38 is selected from hydrogen, alkyl,
- R 7 is (CH 2 ) r R 18
- R 18 is phenyl or pyrimidyl, preferably phenyl, in which at least two of substituents are on adjacent members of the ring and form alkylenedioxy, one or two remaining substituents are lower alkyl or lower alkoxy, preferably methyl or methoxy, more preferably methyl, and the others are hydrogen.
- Y is preferably N
- X is preferably S or O, more preferably S.
- the N-(alkylisoxazolyl)sulfonam ⁇ des can be prepared by condensing an ammoisoxazole with a sulfonyl chloride in dry pyridine with or without the catalyst 4-(dimethylam ⁇ no)pyr ⁇ dine.
- the N-(3,4-d ⁇ methyl-5- isoxazolyDsulfonamides and N-(4,5-d ⁇ methyl-5- ⁇ soxazolyl)sulfonam ⁇ des can be prepared from the corresponding aminodimethylisoxazole, such as 5-am ⁇ no-3,4-dimethyl ⁇ soxazole.
- N-(3,4-d ⁇ methyl-5-isoxa- zolyl)-2-(carbomethoxy)th ⁇ ophene-3-sulfonamide was prepared from 2- methoxycarbonylth ⁇ ophene-3-sulfonyl chloride and 5-am ⁇ no-3,4-d ⁇ methyl- isoxazole in dry pyridine.
- the N-(4-haloisoxazolyl)sulfonam ⁇ des can be prepared by conden ⁇ sation of amino-4-halo ⁇ soxazole with a sulfonyl chloride in THF with sodium hydride as a base.
- N-(4-bromo-3-methyl-5- ⁇ soxazolyl)thiophene-2-sulfonam ⁇ de was prepared from 5-amino-4-bromo- 3-methylisoxazole and thiophene-2-sulfonyl chloride in THF and sodium hydride.
- N-(4-bromo-3-methyl-5- ⁇ soxazolyl)-5-(3- ⁇ soxazolyl)th ⁇ ophene-2- sulfonamide was prepared from 5-am ⁇ no-4-bromo-3-methyl ⁇ soxazole and 5-(3- ⁇ soxazolyl)th ⁇ ophene-2-sulphonyl chloride.
- compounds such as those in which Ar 2 is thienyl, furyl and pyrrolyl herein, may be prepared by reacting an appropriate sulfonyl chloride with a 5-am ⁇ no ⁇ soxazole substituted at the 3 and 4 positions, such as 5-am ⁇ no-4-bromo-3-methyl ⁇ soxazole, in tetrahydrofuran (THF) solution containing a base, such as sodium hydride. Following the reaction, the THF is removed under reduced pressure, the residue dissolved in water, acidified and extracted with methylene chloride. The organic layer is washed and then dried over anhydrous magnesium sulfate, the solvents are evaporated and the residue is purified by recrystallization using hexanes/ethylacetate to yield pure product.
- THF tetrahydrofuran
- sulfonamides also can be prepared from the corresponding sulfonyl chloride and the ammoisoxazole in pyridine with or without a catalytic amount of 4-d ⁇ methylam ⁇ nopyridine (DMAP).
- DMAP 4-d ⁇ methylam ⁇ nopyridine
- the bis-sulfonyl compound is obtained as the major or exclusive product.
- the bis-sulfonated products can be readily hydrolyzed to the sulfonamide using aqueous sodium hydroxide and a suitable co-solvent, such as methanol or tetrahydrofuran, generally at room temperature.
- a th ⁇ eno[2,3- blpy ⁇ dine is reacted with chlorosulfonic acid to produce a th ⁇ eno[2,3-b]- py ⁇ d ⁇ ne-3-sulfonam ⁇ de, which is then reacted with a 4-chloro-5-methyl-3- aminoisoxazole to produce the desired thieno-pyridine.
- Preparation of exemplary thieno-py ⁇ dines is set forth in the EXAMPLES.
- Prodrugs and other derivatives of the compounds suitable for administration to humans may also be designed and prepared by methods known to those of skill in the art (see, e.g. , Nogrady (1 985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392).
- Compounds that exhibit in vitro activities such as the ability to bind to endothelin receptors or to compete with one or more of the endothelin peptides for binding to endo ⁇ thelin receptors can be used in the methods for isolation of endothelin receptors and the methods for distinguishing the specificities of endo ⁇ thelin receptors, and are candidates for use in the methods of treating endothelin-mediated disorders.
- the compounds are tested for the ability to modulate the activity of endothelin- 1 .
- Numerous assays are known to those of skill in the art for evaluating the ability of compounds to modulate the activity of endothelin (see, e.g.. U.S. Patent No. 5, 1 14,91 8 to Ishikawa et aL; EP A1 0 436 1 89 to BANYU PHARMACEUTICAL CO., LTD. (October 7, 1 991 ); Borges et al. ( 1 989) Eur. J. Pharm. 1 65: 223-230; Filep et al. ( 1 991 ) Biochem. Biophvs. Res. Commun. 1 77: 1 71 - 1 76).
- the properties of a potential antagonist may be assessed as a function of its ability to inhibit an endothelin induced activity in vitro using a particular tissue, such as rat portal vein and aorta as well as rat uterus, trachea and vas deferens (see e.g. , Borges, R., Von Grafenstein, H. and Knight, D.E. , "Tissue selectivity of endothelin, " Eur. J. Pharmacol 1 65:223-230, ( 1 989)) .
- the ability to act as an endothelin antagonist in vivo can be tested in hypertensive rats, ddy mice or other recognized animal models (see, Kaltenbronn et aL ( 1 990) J. Med.
- Chem. 33:838- 845 see, also, U.S. Patent No. 5, 1 14,918 to Ishikawa et aL; and EP A1 0 436 1 89 to BANYU PHARMACEUTICAL CO., LTD (October 7, 1 991 ); see, also Bolger et aL (1 983) J. Pharmacol. Exp. Ther. 225291 -309).
- pharmaceutical effectiveness may be evaluated and pharmaceutically effective dosages determined.
- a potential agonist may also be evaluated using in vitro and in vivo assays known to those of skill in the art.
- Endothelin activity can be identified by the ability of a test compound to stimulate constriction of isolated rat thoracic aorta (Borges et aL (1989) "Tissue selectivity of endothelin” Eur. J. Pharmacol. 165: 223-230).
- the endothelium is abraded and ring segments mounted under tension in a tissue bath and treated with endothelin in the presence of the test compound. Changes in endothelin induced tension are recorded. Dose response curves may be generated and used to provide information regarding the relative inhibitory potency of the test compound.
- Other tissues including heart, skeletal muscle, kidney, uterus, trachea and vas deferens, may be used for evaluating the effects of a particular test compound on tissue contraction.
- Endothelin isotype specific antagonists may be identified by the ability of a test compound to interfere with endothelin binding to different tissues or cells expressing different endothelin-receptor subtypes, or to interfere with the biological effects of endothelin or an endothelin isotype (Takavanagi et al. (1 991 ) Reg. Pep. 32: 23-37, Panek et al. ( 1992) Biochem. Biophys. Res. Commun. 183: 566-571 ) .
- ET B re ⁇ ceptors are expressed in vascular endothelial cells, possibly mediating the release of prostacyclin and endothelium-derived relaxing factor (De Nucci et aL ( 1988) Proc. Natl. Acad. Sci. USA 85:9797).
- ET A receptors are not detected in cultured endothelial cells, which express ET B receptors.
- the binding of compounds or inhibition of binding of endothelin to ET B receptors can be assessed by measuring the inhibition of endothelin- 1 -mediated release of prostacyclin, as measured by its major stable metabolite, 6-keto PGF 1 ⁇ , from cultured bovine aortic endothelial cells (see, e.g., Filep et aL ( 1 991 ) Biochem. and Biophys Res. Commun. 1 77: 1 71 -1 76) .
- the relative affinity of the compounds for different endothelin receptors may be evaluated by determining the inhibitory dose response curves using tissues that differ in receptor subtype.
- the relative affinities of the compounds for ET A receptors and ET B receptors have been and can be assessed. Those that possess the desired properties, such as specific inhibition of binding of endothelin-1 , are selected. The selected compounds that exhibit desirable activities may be therapeutically useful and are tested for such uses using the above-described assays from which jn vivo effec ⁇ tiveness may be evaluated (see, e.g., U.S. Patent No. 5,248,807; U.S. Patent No. 5,240,910; U.S. Patent No. 5, 198,548; U.S. Patent No. 5, 1 87, 1 95; U.S. Patent No. 5,082,838; U.S. Patent No.
- the compounds also may be used in methods for identifying and isolating endothelin-specific receptors and aiding in the design of compounds that are more potent endothelin antagonists or agonists or that are more specific for a particular endothelin receptor. 2. Isolation of endothelin receptors
- a method for identifying endothelin receptors is provided.
- one or more of the compounds is linked to a support and used in methods of affinity purification of receptors.
- affinity purification of receptors By selecting compounds with particular specificities, distinct subclasses of ET receptors may be identified.
- One or more of the compounds may be linked to an appropriate resin, such as Affi-gel, covalently or by other linkage, by methods known to those of skill in the art for linking endothelin to such resins (see, Schvartz et aL ( 1990) Endocrinology 126: 3218-3222) .
- the linked compounds can be those that are specific for ET A or ET B receptors or other subclasses of receptors.
- the resin is pre-equilibrated with a suitable buffer generally at a physiological pH (7 to 8).
- a composition containing solubilized receptors from a selected tissue are mixed with the resin to which the compound is linked and the receptors are selectively eluted.
- the receptors can be identified by testing them for binding to an endothelin isopeptide or analog or by other methods by which proteins are identified and characterized. Preparation of the receptors, the resin and the elution method may be performed by modification of standard protocols known to those of skill in the art (see, e.g., Schvartz et aL (1990) Endocrinology 1 26: 321 8-3222). Other methods for distinguishing receptor type based on differential affinity to any of the compounds herein are provided. Any of the assays described herein for measuring the affinity of selected compounds for endothelin receptors may also be used to distinguish receptor subtypes based on affinity for particular compounds provided herein.
- an unknown receptor may be identified as an ET A or ET B receptor by measuring the binding affinity of the unknown receptor for a compound provided herein that has a known affinity for one receptor over the other.
- Such preferential interaction is useful for determining the particular disease that may be treated with a compound prepared as described herein.
- compounds with high affinity for ET A receptors and little or no affinity for ET B receptors are candidates for use as hypertensive agents; whereas, compounds that preferentially interact with ET B receptors are candidates for use as anti-asthma agents.
- Effective concentrations of one or more of the sulfonamide compounds of formula I or II or any formula or compound provided herein or pharmaceutically acceptable salts, esters or other derivatives thereof are mixed with a suitable pharmaceutical carrier or vehicle.
- methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as tween, or dissolution in aqueous sodium bicarbonate.
- cosolvents such as dimethylsulfoxide (DMSO)
- surfactants such as tween
- dissolution in aqueous sodium bicarbonate such as sodium bicarbonate.
- Derivatives of the compounds, such as salts of the compounds or prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
- the concentrations of the compounds are effective for delivery of an amount, upon administration, that ameliorates the symptoms of the endothelin-mediated disease.
- the compositions are formulated for single dosage administration.
- the resulting mixture may be a solution, suspension, emulsion or the like.
- the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle.
- the effective concentration is sufficient for ameliorating the symptoms of the disease, disorder or condition treated and may be empirically determined.
- Pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.
- the compounds may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.
- the active compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid, semi-liquid or solid form and are formulated in a manner suitable for each route of administration.
- Preferred modes of administration include oral and parenteral modes of administration.
- the active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated.
- the therapeutically effective concentration may be determined empirically by testing the compounds in known in vitro and in vivo systems (see, e.g., U.S. Patent No. 5, 1 14,91 8 to Ishikawa et aL; EP A1 0 436 1 89 to BANYU PHARMACEUTICAL CO. , LTD (October 7, 1 991 ); Borges et aL ( 1 989) Eur. J. Pharm. 1 65: 223-230; : Filep et al. ( 1 991 ) Biochem. Biophys. Res. Commun. 1 77: 1 71 -176) and then extrapolating therefrom for dosages for humans.
- the concentration of active compound in the drug composition will depend on absorption, inactivation and excretion rates of the active compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art. For example, the amount that is delivered is sufficient to treat the symptoms of hypertension.
- the effective amounts for treating endothelin-mediated disorders are expected to be higher than the amount of the sulfonamide compound that would be administered for treating bacterial infections.
- a therapeutically effective dosage should produce a serum concentration of active ingredient of from about 0.1 ng/ml to about 50- 1 00 ⁇ g/ml.
- the pharmaceutical compositions typically should provide a dosage of from about 0.01 mg to about 2000 mg of compound per kilogram of body weight per day.
- the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated .
- the compound should be provided in a composition that protects it from the acidic environment of the stomach.
- the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine.
- the composition may also be formulated in combination with an antacid or other such ingredient.
- Oral compositions will generally include an inert diluent or an edible carrier and may be compressed into tablets or enclosed in gelatin capsules.
- the active compound or compounds can be incorporated with excipients and used in the form of tablets, capsules or troches. Pharmaceutically compatible binding agents and adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder, such as microcrystalline cellulose, gum tragacanth and gelatin; an excipient such as starch and lactose, a disintegrating agent such as, but not limited to, alginic acid and corn starch; a lubricant such as, but not limited to, magnesium stearate; a glidant, such as, but not limited to, colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; and a flavoring agent such as peppermint, methyl salicylate, and fruit flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth and gelatin
- an excipient such as starch and lactose, a disintegrating agent such as, but not limited to, alginic acid and corn starch
- a lubricant such as, but not limited to, magnesium stearate
- the dosage unit form When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil.
- dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
- the compounds can also be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
- a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
- the active materials can also be mixed with other active materials which do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics.
- materials that supplement the desired action such as antacids, H2 blockers, and diuretics.
- the compound may be used with other bronchodilators and antihypertensive agents, respectively.
- Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include any of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- a sterile diluent such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent
- antimicrobial agents such as benzyl alcohol and methyl parabens
- antioxidants such as ascorbic acid and sodium bisul
- suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
- PBS physiological saline or phosphate buffered saline
- suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
- Liposomal suspensions, including tissue-targeted liposomes may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. For example, liposome formulations may be prepared as described in U.S. Patent No. 4,522,81 1 .
- the active compounds may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings.
- Such carriers include controlled release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparation of such formulations are known to those skilled in the art.
- the compounds may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application.
- Such solutions may be formulated as 0.01 % - 1 0% isotonic solutions, pH about 5-7, with appropriate salts.
- the compounds may be formulated as aerosols for topical application, such as by inhalation (see, e ⁇ ., U.S. Patent Nos. 4,044, 1 26, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment inflammatory diseases, particularly asthma).
- the compounds may be packaged as articles of manufacture containing packaging material, a compound provided herein, which is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting binding of an endothelin peptide to an ET receptor with an IC 50 of less than about 10 ⁇ M, within the packaging material, and a label that indicates that the compound or salt thereof is used for antagonizing the effects of endothelin, treating endothelin-mediated disorders or inhibiting the binding of an endothelin peptide to an ET receptor.
- reaction solution was slowly warmed to -30°C over a 45 minute period followed by the addition of bromoethane (0.25 ml, 3.4 mmoles) .
- the solution was stirred 2 hours at ambient temperature then diluted with EtOAc (50 ml) and washed with H 2 O (75 ml).
- the organic phase was dried (MgSO 4 ), filtered and concentrated to collect 0.41 g (97%) of the title compound as an orange-brown oil.
- N-(4-chloro-5-methyl-3-isoxazolyl)-2-ethylthieno[2,3-b]pyridine-3- suifonamide was prepared according to Example 1 (C), using NaH (44 mg, 1 .9 mmoles), THF (5 ml), 4-chloro-5-methyl-3-aminoisoxazole (82 mg, 0.62 mmoles) and 2-ethylthieno[2,3-b]pyridine-3-sulfonyl chloride (0.1 9 g, 0.71 mmoles). Flash chromatography (50% EtOAc/hexanes) followed by recrystallization from EtOAc/hexanes provided 78 mg (35%) of the title compound as a light yellow solid, m.p. 1 72- 1 74°C.
- N-(4-chloro-3-methyl-5-isoxazolyl)thieno[2,3-b]pyridine-3- sulfonamide was prepared by the method of Example 1(C) using NaH (0. 1 6 g, 6.8 mmoles), THF ( 1 0 ml), 4-chloro-3-methyl-5-aminoisoxazole
- N- ⁇ 4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyethoxy- methyl)thieno[2,3-b]pyridine-3-sulfonamide To a solution of N-(4-chloro-3-methyl-5-isoxazolyl)thieno[2,3-b]- pyridine-3-sulfonamide (0.76 g, 2.3 mmoles) (see Example 3), DIEA (0.6 ml, 35 mmoles) and EtOAc ( 100 ml) was added methoxyethoxymethyl-CI (0.3 ml, 2.5 mmoles).
- Example 4(B) N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyethoxy- methyl)thieno[2,3-b]pyridine-3-sulfonamide (0.31 g, 0.75 mmolesHExample 4(A)], THF (4 ml), r-Bu ⁇ ( 1 .7 M, 0.53 ml, 0.90 mmoles) and 2-methyl-4,5-(methylenedioxy)benzaldehyde (0.1 5 g, 0.90 mmoles) . Flash chromatography (40% EtOAc/hexanes) provided 0.1 6 g (38%) of the title compound.
- the title compound was prepared by the method of Example 5(A), using N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyethoxymethyl)-2-[ ⁇ - hydroxy-2-methyl-4,5-(methylenedioxy)benzyl]thieno[2,3-b]pyridine-3- sulfonamide (0.1 6 g, 0.28 mmoles), CH 2 CI 2 (3 ml), triethylsilane (0.45 ml, 2.8 mmoles) and boron trifluoride etherate (0.1 7 ml, 1 .4 mmoles).
- Example 4(B) N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyethoxy- methyl)thieno[2,3-b]pyridine-3-sulfonamide (0.1 8 g, 0.42 mmoles)[Example 4(A)], f-BuLi ( 1 .7 M, 0.32 ml, 0.55 mmoles), THF (5 ml) and 2,4-dimethylbenzaldehyde (0.1 2 ml, 0.84 mmoles) . Flash chromatography (40% EtOAc/hexanes) provided 0. 1 7 g (73%) of the title compound.
- the title compound was prepared by the method of Example 5(A) using N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyethoxymethyl)-2-[ ⁇ - hydroxy-2,4-dimethylbenzyl]thieno[2,3-b]pyridine-3-sulfonamide (0.1 7 g, 0.31 mmoles), CH 2 CI 2 (5 ml), triethylsilane (0.5 ml, 3.1 mmoles) and boron trifluoride etherate (0.2 ml, 1 .5 mmoles). Flash chromatography (40% EtOAc/hexanes) provided 87 mg (53%) of the title compound.
- the title compound was prepared by the method of Example 1 (C) using NaH (0.12 g, 4.9 mmoles), THF (6 ml), 4-chloro-5-methyl-3- aminoisoxazole (0.26 g, 2.0 mmoles) and thieno[2,3-b]pyridine-3-sulfonyl chloride (0.50 g, 2. 1 mmoles), giving 0.30 g (47%) of the title compound as an orange-brown oil.
- the title compound was prepared by the method of Example 4(A) using N-(4-chloro-5-methyl-3-isoxazolyl)thieno[2,3-b]pyridine-3- sulfonamide (0.30 g, 0.91 mmoles), EtOAc (30 ml), DIEA (0.24 ml, 1 .4 mmoles) and MEM-CI (0.1 1 ml, 1 .0 mmoles). Flash chromatography
- the title compound was prepared by the method of Example 4(B) using N-(4-chloro-5-methyl-3-isoxazolyl)-N-(methoxyeth- oxymethyl)thieno[2,3-b]pyridine-3-sulfonamide (0.23 g, 0.54 mmoles), THF (5 ml), f-BuLi ( 1 .7 M, 0.41 ml, 0.70 mmoles) and 2-methyl-4, 5-
- the title compound was prepared by the method of Example 5(A) using N-(4-chloro-5-methyl-3-isoxazolyl)-N-(methoxyethoxymethyl)-2-[ ⁇ - hydroxy-2-methyl-4,5-(methylenedioxy)benzyl]thieno[2,3-b]pyridine-3- sulfonamide (0.1 1 g, 0.1 9 mmoles), CH 2 CI 2 (5 ml), triethyl silane (0.31 ml, 1 .9 mmoles) and boron trifluoride etherate (0.1 2 ml, 0.97 mmoles).
- reaction solution was stirred 2 hours at ambient temperature, then diluted with EtOAc (50 ml) and washed with 2% HCI (2 x 100 ml). The organic layer was dried (MgSO 4 ), filtered and concentrated to collect
- the title compound was prepared by the method of Example 5(A) using N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyethoxymethyl)-2- ⁇ - acetoxy-2-[2-(acetoxy)ethyl]-4,5-(methylenedioxy)benzyl ⁇ thieno[2,3-b]- pyridine-3-sulfonamide (0.1 3 g, 0.1 9 mmoles), CH 2 CI 2 (3 ml), triethylsilane (0.30 ml, 1 .9 mmoles) and boron trifluoride etherate (0.1 2 ml, 0.95 mmoles), giving 0.1 2 g (96%) of the title compound as a yellow oil.
- the title compound was prepared by the method of Example 9(C) using N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyethoxymethyl)-2-( ⁇ - hydroxynaphthlymethyl)thieno[2,3-b]pyridine-3-sulfonamide (0.10 g, 0.1 8 mmoles), pyridine (3 ml) and acetic anhydride (0.5 ml) . 97 mg
- Example 4(B) N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyethoxy- methyl)-2- ⁇ -hydroxy-2,6-dimethoxybenzyl)thieno[2,3-b]- pyridine-3-sulfonamide
- the title compound was prepared by the method of Example 4(B) using N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyeth- oxymethyl)thieno[2,3-b]pyridine-3-sulfonamide (0.1 5 g, 0.35 mmoles) [Example 4(A)], THF (5 ml), /7-Bu ⁇ (2.5 M, 0.1 6 ml, 0.41 mmoles) and 2,6-dimethoxybenzaldehyde (88 mg, 0.53 mmoles).
- Example 4(B) N-(4-chloro-3-methyl-5-isoxazolyl)-N-(methoxyeth- oxymethyl)thieno[2,3-b]pyridine (0.40 g, 0.96 mmoles)[Example 4(A)], THF ( 10 ml), ⁇ ?-BuLi (2.5 M, 0.42 ml, 1 . 1 mmoles) and 3-(3,4- methylenedioxyphenyDpropionaldehyde (0.20 g, 1 . 1 mmoles) . Flash chromatography (50% EtOAc/hexanes) provided 0.51 g (89%) of the title compound as a light yellow solid.
- Compounds that are potential endothelin antagonists are identified by testing their ability to compete with 125 l-labeled ET-1 for binding to human ET A receptors or ET B receptors present on isolated cell membranes.
- the effectiveness of the test compound as an antagonist or agonist of the biological tissue response of endothelin can also be assessed by measuring the effect on endothelin induced contraction of isolated rat thoracic aortic rings.
- the ability of the compounds to act as antagonists or agonists for ET B receptors can be assessed by testing the ability of the compounds to inhibit endothelin-1 induced prostacyclin release from cultured bovine aortic endothelial cells.
- TE 671 cells (ATCC Accession No. HTB 1 39) express ET A receptors. These cells were grown to confluence in T- 1 75 flasks. Cells from multiple flasks were collected by scraping, pooled and centrifuged for 10 min at 1 90 X g. The cells were resuspended in phosphate buffered saline (PBS) containing 10 mM EDTA using a Tenbroeck homogenizer.
- PBS phosphate buffered saline
- the suspension was centrifuged at 4°C at 57,800 X g for 1 5 min, the pellet was resuspended in 5 ml of buffer A (5mM HEPES buffer, pH 7.4 containing aprotinin ( 100 KlU/ml)) and then frozen and thawed once.
- buffer A 5mM HEPES buffer, pH 7.4 containing aprotinin ( 100 KlU/ml)
- Buffer B 5 mM HEPES Buffer, pH 7.4 containing 10 mM MnCI 2 and 0.001 % deoxyribonuclease Type 1
- Buffer B 5 mM HEPES Buffer, pH 7.4 containing 10 mM MnCI 2 and 0.001 % deoxyribonuclease Type 1
- the mixture was centrifuged at 57,800 X g as described above, the pellet washed twice with buffer A and then resuspended in buffer C (30 mM HEPES buffer, pH 7.4 containing aprotinin ( 100 KlU/ml)) to give a final protein concentration of 2 mg/ml and stored at - 70°C until use.
- buffer C (30 mM HEPES buffer, pH 7.4 containing aprotinin ( 100 KlU/ml)
- the membrane suspension was diluted with binding buffer (30 mM HEPES buffer, pH 7.4 containing 1 50 mM NaCl, 5mM MgCI 2 , 0.5% Bacitracin) to a concentration of 8 ⁇ g/50 ⁇ l.
- binding buffer (30 mM HEPES buffer, pH 7.4 containing 1 50 mM NaCl, 5mM MgCI 2 , 0.5% Bacitracin) to a concentration of 8 ⁇ g/50 ⁇ l.
- 125 l-endothelin- 1 (3,000 cpm, 50 ml) was added to 50 ⁇ l of either: (A) endothelin-1 (for non specific binding) to give a final concentration 80 nM; (B) binding buffer (for total binding); or (C) a test compound (final concentration 1 nM to 100 ⁇ M).
- the degree of inhibition of binding (D) was calculated according to the following equation:
- COS7 cells were transfected with DNA encoding the ET B receptor
- the resulting cells which express the human ET B receptor, were grown to confluence in T- 1 50 flasks.
- Membrane was prepared as described above.
- the binding assay was performed as described above using the membrane preparation diluted with binding buffer to a concentration of 1 ⁇ g/50 ⁇ l.
- the COS7 cells described above, that had been transfected with DNA encoding the ET B receptor and express the human ET B receptor on their surfaces were grown to confluence in T-1 75 flasks. Cells from multiple flasks were collected by scraping, pooled and centrifuged for 10 min at 1 90 X g. The cells were resuspended in phosphate buffered saline (PBS) containing 10 mM EDTA using a Tenbroeck homogenizer.
- PBS phosphate buffered saline
- the suspension was centrifuged at 4°C 57,800 X g for 1 5 min, the pellet was resuspended in 5 ml of buffer A (5mM HEPES buffer, pH 7.4 containing aprotinin ( 1 00 KlU/ml) and then frozen and thawed once.
- buffer A 5mM HEPES buffer, pH 7.4 containing aprotinin ( 1 00 KlU/ml) and then frozen and thawed once.
- Buffer B 5 mM HEPES Buffer, pH 7.4 containing 10 mM MnCI 2 and 0.001 % deoxyribonuclease Type 1 ) was added, the suspension mixed by inversion and then incubated at 37°C for 30 minutes.
- the mixture was centrifuged at 57,800 X g as described above, the pellet washed twice with buffer A and then resuspended in buffer C (30 mM HEPES buffer, pH 7.4 containing aprotinin ( 100 KlU/ml) to give a final protein concentration of 2 mg/ml.
- the binding assay was performed as described above using the membrane preparation diluted to give 1 ⁇ g/50 ⁇ l of binding buffer.
- test compound as an antagonist or agonist of the biological tissue response of endothelin also is assessed by measuring the effect on endothelin induced contraction of isolated rat thoracic aortic rings (see, e.g. , Borges et aL ( 1 989) Eur. J. Pharmacol. 1 65:223-230) or by measuring the ability to contract the tissue when added alone.
- Compounds to be tested are prepared as 1 00 ⁇ M stocks. If necessary to effect dissolution, the compounds are first dissolved in a minimum amount of DMSO and diluted with 1 50 mM NaCl. Because DMSO can cause relaxation of the aortic ring, control solutions containing varying concentrations of DMSO were tested.
- the thoracic portion of the adult rat aorta is excised, the endothelium abraded by gentle rubbing and then cut into 3 mm ring segments. Segments are suspended under a 2 g preload in a 10 ml organ bath filled with Krebs'- Henseleit solution saturated with a gas mixture of 95% O 2 and 5% CO 2 ( 1 18 mM NaCl, 4.7 mM KCl, 1 .2 mM MgSO 4 , 1 .2 mM KH 2 PO 4 , 25 mM NaHCO 3 , 2.5 mM CaCI 2 , 10 mM D- glucose).
- the pA 2 is a linear function of the log of the IC 50 .
- endothelin-1 stimulates the release of prostacyclin from cultured bovine aortic endothelial cells
- the compounds that have agonist or antagonist activity are identified by their ability to inhibit endothelin-1 induced prostacyclin release from such endothelial cells by measuring 6- keto PGF 1 ⁇ substantially as described by (Filep et al. ( 1 991 ) Biochem. Biophys. Res. Commun. 1 77 1 71 - 1 76.
- Bovine aortic cells are obtained from collagenase-treated bovine aorta, seeded into culture plates, grown in Medium 1 99 supplemented with heat inactivated 1 5% fetal calf serum, and L-glutamine (2 mM), penicillin, streptomycin and fungizone, and subcultured at least four times. The cells are then seeded in six-well plates in the same medium. Eight hours before the assay, after the cells reach confluence, the medium is replaced. The cells are then incubated with a) medium alone, b) medium containing endothelin-1 ( 10 nM), c) test compound alone, and d) test compound + endothelin-1 ( 10 nM).
- Sarafotoxin 6c is a specific ET B antagonist that contracts rat fundal stomach strips.
- the effectiveness of test compounds to inhibit this sarafotoxin 6c-induced contraction of rat fundal stomach strips is used as a measure ET B antagonist activity.
- Two isolated rat fundal stomach strips are suspended under a 1 g load in a 10 ml organ bath filled with Krebs'-Henseleit solution containing 10 ⁇ M cyclo(D-Asp-Pro-D-Val-Leu-D- Trp) (BQ- 1 23; see, U.S. Patent No.
- DOCA 47 mg are prepared according to the method of Ornmsbee et al. (( 1 973) the J. Pharm. Sci. 62:255-257) . Briefly, DOCA is incorporated into silicon rubber implants for sustained release. To prepare the implants the DOCA is incorporated into unpolymerized silicone rubber, catalyst is added and the mixture is cast in a hemicylindrical shape. Sprague Dawley rats (7-8 weeks old) are unilaterally nephrectomized under ketamine anesthesia and a DOCA-implant is placed on the left lateral dorsal abdomen of the animal. The rats are allowed to recover for about three weeks.
- catheters are inserted under brevital anesthesia into the right femoral artery for measurement of blood pressure, and into the right femoral vein for administration of a selected compound.
- the animals are placed in a restrainer and allowed to recover for a minimum of 60 min or until a steady mean arterial blood pressure is recorded.
- the selected compound or control vehicle is administered either intravenously, as a 60 minute infusion, or orally by oral gavage. Blood pressure was recorded continuously for a further 1 0 hrs.
- MAP mean arterial pressure
- cannulae 50 mg/kg, IP
- cannulae were placed in the femoral artery to measure mean arterial pressure (MAP) and in the femoral vein for intravenous drug administration.
- Animals are placed in a restrainer and allowed to regain consciousness.
- autonomic blockade is administered (atropine methyl nitrate, 3 mg/kg, IV, followed by propranalol, 2 mg/kg, IV) .
- An hour later animals receive a bolus injection of vehicle (0.5 ml) followed thirty minutes later by intravenous bolus administration of ET-1 (Control, 1 ⁇ g/kg) .
- test - compounds are administered by intravenous bolus administration (0.5 ml) and then re-challenged with ET-1 thirty minutes later. Results are expressed as the percent inhibition of the ET- 1 -induced pressor response after administration of the test compound compared to the pressor response induced by the control ET-1 challenge. In some cases a third ET- 1 challenge is administered ninety minutes after administration of the test compound.
- the IC 50 for each of the compounds of the preceding Examples for ET A and ET B receptors has been measured. Almost all of the compounds have an IC 50 of less than 1 0 ⁇ M and many have an IC 50 less than about 1 ⁇ M for either or both of the ET A and ET B receptors. A number of the compounds have an IC 50 for one receptor sub-type that is substantially less (at least 10-fold or more) than for the other receptor sub-type. Thus, these compounds are selective for either the ET A receptor sub-type or the ET B receptor sub-type.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69726272T DE69726272D1 (en) | 1996-04-15 | 1997-04-09 | THIENOPYRIDINE SULPHONAMIDE DERIVATIVES, RELATED COMPOUNDS FOR MODULATING ENDOTHELIN INACTIVITY |
AT97918564T ATE254619T1 (en) | 1996-04-15 | 1997-04-09 | THIENOPYRIDINE SULPHONAMIDE DERIVATIVES, RELATED COMPOUNDS FOR MODULATING ENDOTHELIN ACTIVITY |
EP97918564A EP0898571B1 (en) | 1996-04-15 | 1997-04-09 | Thieno-pyridine sulfonamides, derivatives thereof and related compounds that modulate the activity of endothelin |
AU26641/97A AU2664197A (en) | 1996-04-15 | 1997-04-09 | Thieno-pyridine sulfonamides, derivatives thereof and related compounds that modulate the activity of endothelin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US632,586 | 1996-04-15 | ||
US08/632,586 US5804585A (en) | 1996-04-15 | 1996-04-15 | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997039000A1 true WO1997039000A1 (en) | 1997-10-23 |
Family
ID=24536121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/005994 WO1997039000A1 (en) | 1996-04-15 | 1997-04-09 | Thieno-pyridine sulfonamides, derivatives thereof and related compounds that modulate the activity of endothelin |
Country Status (6)
Country | Link |
---|---|
US (4) | US5804585A (en) |
EP (1) | EP0898571B1 (en) |
AT (1) | ATE254619T1 (en) |
AU (1) | AU2664197A (en) |
DE (1) | DE69726272D1 (en) |
WO (1) | WO1997039000A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049289A1 (en) * | 1999-12-31 | 2001-07-12 | Texas Biotechnology Corporation | Pharmaceutical and veterinary uses of endothelin antagonists |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6686382B2 (en) | 1999-12-31 | 2004-02-03 | Encysive Pharmaceuticals Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US8017781B2 (en) | 2005-11-15 | 2011-09-13 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
US11492346B2 (en) | 2019-06-18 | 2022-11-08 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
US11911372B2 (en) | 2018-06-28 | 2024-02-27 | Ctxt Pty Ltd | Compounds |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
US5958905A (en) | 1996-03-26 | 1999-09-28 | Texas Biotechnology Corporation | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
IL131318A (en) | 1997-04-28 | 2004-08-31 | Encysive Pharmaceuticals Inc | Pharmaceutically acceptable salts of sulfonamides for treatment of endothelin-mediated disorders |
AU759641B2 (en) * | 1998-08-19 | 2003-04-17 | Skyepharma Canada Inc. | Injectable aqueous dispersions of propofol |
US7180849B2 (en) * | 2001-05-18 | 2007-02-20 | Sharp Kabushiki Kaisha | Optical storage medium enabling uniform light transmittance, optical read/write apparatus for same, and optical read/write method for same |
JP5138938B2 (en) * | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Compounds and methods for the development of RET modulators |
US20070066641A1 (en) * | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
CA2570817A1 (en) * | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
JP2008545652A (en) * | 2005-05-17 | 2008-12-18 | プレキシコン,インコーポレーテッド | Compounds that modulate c-kit and c-fms activity and uses thereof |
ES2371397T3 (en) * | 2005-06-22 | 2011-12-30 | Plexxikon, Inc. | PIRROLO DERIVATIVES [2,3-B] PIRIDINE AS INHIBITORS OF PROTEIN KINES. |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
WO2008080015A2 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20121126A1 (en) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
AU2008276063B2 (en) | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
AR078033A1 (en) | 2009-04-03 | 2011-10-12 | Plexxikon Inc | A SOLID DISPERSION, CONTAINING THE COMPOUND {3- [5- (4- (CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDA OF PROPANE-1-SULPHONIC ACID, COMPOSITIONS AND FORMULATIONS THAT INCLUDE SUCH SOLID DISPERSION; METHODS FOR MANUFACTURING SUCH SOLID DISPERSION, FORMS 1 AND 2 |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
PE20141360A1 (en) | 2011-02-07 | 2014-10-13 | Plexxikon Inc | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND INDICATIONS FOR THEM. |
TWI558702B (en) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | Solid forms of a pharmaceutically active substance |
JP5382053B2 (en) * | 2011-04-15 | 2014-01-08 | 株式会社安川電機 | Robot system and inspection method using robot system |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9170126B2 (en) * | 2013-05-10 | 2015-10-27 | Garmin International, Inc. | Avionics navigation power range indicator |
US20180187263A1 (en) | 2017-01-05 | 2018-07-05 | Iowa State University Research Foundation, Inc. | Kits for diagnostic detection and prevention of feedlot bovine respiratory disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994027979A1 (en) * | 1993-05-20 | 1994-12-08 | Immunopharmaceutics, Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB804036A (en) * | 1956-03-02 | 1958-11-05 | Hoffmann La Roche | A process for the manufacture of a sulphanilamide of the isoxazole series |
US2888455A (en) * | 1956-09-04 | 1959-05-26 | Shionogi & Co | New sulfonamide and process for producing the same |
US3300488A (en) * | 1963-12-23 | 1967-01-24 | Shionogi & Co | Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas |
US3660383A (en) * | 1968-08-14 | 1972-05-02 | Shionogi & Co | Production of iodoisoxazole compounds |
US4044126A (en) * | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) * | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US3821087A (en) * | 1972-05-18 | 1974-06-28 | Dedrick R | Cell culture on semi-permeable tubular membranes |
US3883393A (en) * | 1972-05-18 | 1975-05-13 | Us Health Education & Welfare | Cell culture on semi-permeable tubular membranes |
GB1473433A (en) * | 1975-10-09 | 1977-05-11 | Banyu Pharmaceutical Co Ltd Hi | |
FR2395271A1 (en) * | 1977-06-21 | 1979-01-19 | Parcor | PROCESS FOR THE PREPARATION OF THIENO (2,3-C) AND THIENO (3,2-C) PYRIDINES |
US4191554A (en) * | 1977-10-03 | 1980-03-04 | E. I. Du Pont De Nemours And Company | Herbicidal benzamides |
US4375544A (en) * | 1978-01-28 | 1983-03-01 | Croda Synthetic Chemicals Limited | Fused pyridines |
FR2471983A1 (en) * | 1979-12-20 | 1981-06-26 | Sanofi Sa | PROCESS FOR THE CATALYTIC PREPARATION OF THIENO (3,2-C) PYRIDINE |
US4577014A (en) * | 1981-09-08 | 1986-03-18 | Eli Lilly And Company | Thieno and furopyridinium-substituted cephalosporins |
US4406898A (en) * | 1981-09-08 | 1983-09-27 | Eli Lilly And Company | Oxazole and oxadiazole cephalosporins |
EP0076072B1 (en) * | 1981-09-24 | 1987-05-13 | BEECHAM - WUELFING GmbH & Co. KG | Sulphonamides |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JPS60188084A (en) * | 1984-03-08 | 1985-09-25 | Otsuka Pharmaceut Factory Inc | Asterric acid derivative |
JPS60188088A (en) * | 1984-03-09 | 1985-09-25 | Ensuikou Seito Kk | Preparation of cyclodextrin |
US4585773A (en) * | 1984-07-11 | 1986-04-29 | Bristol-Myers Company | Isoindolinyl-alkyl-piperazines |
US4659369A (en) | 1984-08-27 | 1987-04-21 | E. I. Du Pont De Nemours And Company | Herbicidal acetals and ketals |
US4753672A (en) | 1985-07-16 | 1988-06-28 | E. I. Du Pont De Nemours And Company | Herbicidal acetals and ketals |
US4861366A (en) | 1984-08-27 | 1989-08-29 | E. I. Du Pont De Nemours And Company | Herbicidal acetals and ketals |
EP0194548A3 (en) * | 1985-03-12 | 1988-08-17 | Dr. Karl Thomae GmbH | Sulfonylaminoethyl compounds, medicines containing these compounds and process for their preparation |
US4914112A (en) | 1986-06-03 | 1990-04-03 | Sumitomo Pharmaceuticals Company, Limited | Aminoazole derivatives and their production and use |
US4769371A (en) * | 1987-05-01 | 1988-09-06 | E. R. Squibb & Sons, Inc. | Dihydropyrimidine carboxylic acid esters |
US4752613A (en) * | 1987-08-03 | 1988-06-21 | E. R. Squibb & Sons, Inc. | Sulphonamidothienylcarboxylic acid compounds |
US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US5260278A (en) * | 1988-05-27 | 1993-11-09 | Warner-Lambert Company | Diol-containing renin inhibitors |
US5231166A (en) * | 1988-10-25 | 1993-07-27 | Takeda Chemical Industries, Ltd. | Endothelin |
US5246931A (en) * | 1988-10-25 | 1993-09-21 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
US4997836A (en) * | 1988-11-11 | 1991-03-05 | Takeda Chemical Industries, Ltd. | Trisubstituted piperazine compounds, their production and use |
WO1990009380A1 (en) * | 1989-02-10 | 1990-08-23 | Otsuka Pharmaceutical Co., Ltd. | Indole derivatives, preparation thereof, and drug for preventing and treating nephritis containing same |
US5026700A (en) * | 1989-05-16 | 1991-06-25 | Merrell Dow Pharmaceuticals | Certain quinolines and thienopyridines as excitatory amino acid antagonists |
US5082838A (en) * | 1989-06-21 | 1992-01-21 | Takeda Chemical Industries, Ltd. | Sulfur-containing fused pyrimidine derivatives, their production and use |
JPH0347163A (en) * | 1989-06-30 | 1991-02-28 | Fujisawa Pharmaceut Co Ltd | Anthraquinone derivative and production thereof |
US5230999A (en) * | 1989-07-24 | 1993-07-27 | Takeda Chemical Industries, Ltd. | Monoclonal antibody to endothelin-3 or precursor thereof and use thereof |
CA2032559C (en) * | 1989-12-28 | 2001-11-06 | Kiyofumi Ishikawa | Endothelin antagonistic cyclic pentapeptides |
US5284828A (en) * | 1990-05-14 | 1994-02-08 | Fujisawa Pharmaceutical Co. Ltd. | Peptide compound and its preparation |
US5430022A (en) * | 1990-05-14 | 1995-07-04 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compound and its preparation |
CA2043741C (en) * | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
JPH04134084A (en) * | 1990-09-21 | 1992-05-07 | Tousou Sangyo Kk | Silicic acid ester and its production |
CA2056142A1 (en) * | 1990-11-27 | 1992-05-28 | Hirotomo Masuya | Pyridopyridazine compounds and their use |
CA2059380A1 (en) * | 1991-01-24 | 1992-07-25 | Yiu-Kuen T. Lam | Endothelin receptor antagonists isolated from microbispora |
DK0526642T3 (en) * | 1991-01-29 | 1998-10-19 | Shionogi & Co | triterpene derivative |
EP0569487A1 (en) * | 1991-01-31 | 1993-11-18 | Abbott Laboratories | Endothelin converting enzyme inhibitors |
DK0498722T3 (en) * | 1991-02-07 | 1998-03-09 | Roussel Uclaf | New bicyclic nitrogen compounds substituted with a benzyl group, process for their preparation, the novel intermediates obtained, their use as drugs and the pharmaceutical compositions contained in them. |
CA2061246A1 (en) * | 1991-02-15 | 1992-08-16 | Mitsuhiro Wakimasu | Peptides having antagonistic activities to endothelin receptors, production and use thereof |
CA2104860A1 (en) * | 1991-03-08 | 1992-09-09 | Thomas T. Andersen | Endothelin antagonists |
TW270116B (en) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
US5382569A (en) * | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
RU2086544C1 (en) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity |
US5260276A (en) * | 1991-06-14 | 1993-11-09 | Warner-Lambert Company | Linear and monocyclic endothelin antagonists |
FR2679906B1 (en) * | 1991-07-31 | 1995-01-20 | Adir | NOVELS (ISOQUINOLEIN-5 YL) SULFONAMIDES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
GB2259450A (en) * | 1991-09-11 | 1993-03-17 | Fujisawa Pharmaceutical Co | Compositions with endothelin antagonist activity |
JP2667294B2 (en) * | 1991-11-05 | 1997-10-27 | スミスクライン・ビーチャム・コーポレイション | Endothelin receptor antagonist |
US5198548A (en) * | 1992-01-30 | 1993-03-30 | Warner-Lambert Company | Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof |
FR2687675B1 (en) * | 1992-01-31 | 1997-04-18 | Roussel Uclaf | NOVEL BICYCLIC PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THE NEW INTERMEDIATES OBTAINED, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2687156B1 (en) * | 1992-02-12 | 1994-04-01 | Roussel Uclaf | NOVEL PEPTIDE DERIVATIVES, PROCESS FOR THE PREPARATION AND APPLICATION AS MEDICAMENTS OF SUCH NEW DERIVATIVES. |
US5378715A (en) * | 1992-02-24 | 1995-01-03 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
TW224462B (en) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
LT3200B (en) * | 1992-03-18 | 1995-03-27 | Takeda Chemical Industries Ltd | Triazolopyridazine methodfor production thereof and use |
US5240910A (en) * | 1992-04-17 | 1993-08-31 | Merck & Co., Inc. | Antihypertensive compounds produced by fermentation |
US5514696A (en) | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
WO1993023404A1 (en) | 1992-05-19 | 1993-11-25 | Immunopharmaceutics, Inc. | Compounds that modulate endothelin activity |
ES2042421B1 (en) * | 1992-05-22 | 1994-08-01 | Uriach & Cia Sa J | PROCEDURE FOR OBTAINING 8-CHLORINE-11- * 1 - * (5-METHYL-3-PIRIDIL) METHYL * -4-PIPERIDILIDEN * -6,11-DIHYDRO-5H-BENZO * 5,6 * CYCLOHEPTA * 1 , 2-B * PIRIDINE. |
WO1994003483A1 (en) * | 1992-07-30 | 1994-02-17 | Chiron Corporation | Endothelin receptor-binding compounds |
IS2334B (en) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl protease inhibitor of a new class of sulfonamides |
TW287160B (en) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
US5420123A (en) * | 1992-12-21 | 1995-05-30 | Bristol-Myers Squibb Company | Dibenzodiazepine endothelin antagonists |
US5352800A (en) * | 1993-03-11 | 1994-10-04 | Merck & Co., Inc. | Process for the production of a novel endothelin antagonist |
US5420133A (en) * | 1993-03-19 | 1995-05-30 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
US5334598A (en) * | 1993-03-19 | 1994-08-02 | Merck & Co., Inc. | Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives |
US5565485A (en) * | 1993-03-19 | 1996-10-15 | Merck & Co., Inc. | Biphenyl compounds useful or endothelin antagonists |
ES2062943B1 (en) * | 1993-03-23 | 1995-11-16 | Uriach & Cia Sa J | NEW DERIVATIVES OF (2-METHYL-3-PIRIDIL) CYANOMETILPIPERAZINES. |
FI941826A (en) | 1993-04-21 | 1994-10-22 | Takeda Chemical Industries Ltd | Methods and compositions for the prevention and / or therapeutic treatment of organ hypofunction |
US6030991A (en) | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
FR2707089B1 (en) * | 1993-06-30 | 1995-08-18 | Adir | New phosphonic acid derivatives, process for their preparation and pharmaceutical compositions containing them. |
US5391566A (en) * | 1993-07-20 | 1995-02-21 | Merck & Co., Inc. | Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives |
US5686478A (en) * | 1993-07-20 | 1997-11-11 | Merck & Co. Inc. | Endothelin antagonists |
US5389620A (en) * | 1993-08-18 | 1995-02-14 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives |
KR960703901A (en) | 1993-08-19 | 1996-08-31 | 로즈 암스트롱 | Substituted 2 (5H) furanone, 2 (5H) thiophenone and 2 (5H) pyrrolone derivatives, methods for their preparation and their use as endothelin antagonists (Substituted 2 (5H) Furanone, 2 (5H) Thiophenone and 2 (5H) Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists) |
US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
IL111613A0 (en) * | 1993-11-12 | 1995-01-24 | Rhone Poulenc Rorer Ltd | Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them |
US6063911A (en) | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
IL111959A (en) * | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
WO1995024385A1 (en) * | 1994-03-07 | 1995-09-14 | Vertex Pharmaceuticals Incorporated | Sulphonamide derivatives as aspartyl protease inhibitors |
GB9504854D0 (en) | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
JP2930731B2 (en) | 1994-12-20 | 1999-08-03 | エフ・ホフマン−ラ ロシュ アーゲー | Aryl- and heteroaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists |
IL116916A (en) * | 1995-02-06 | 2000-09-28 | Bristol Myers Squibb Co | Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same |
US5599811A (en) * | 1995-02-21 | 1997-02-04 | Warner-Lambert Company | Benzothiazine dioxides as endothelin antagonists |
DE19509950A1 (en) * | 1995-03-18 | 1996-09-19 | Merck Patent Gmbh | Endothelin receptor antagonists |
NZ306734A (en) * | 1995-04-04 | 2000-01-28 | Texas Biotechnology Corp | |
UA58494C2 (en) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical composition, process for preparing thereof and method for endothelin influence counteraction |
GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
US5922759A (en) | 1996-06-21 | 1999-07-13 | Warner-Lambert Company | Butenolide endothelin antagonists |
JPH09124620A (en) | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | Substituted biphenylsulfonamide endothelin antagonist |
BR9612061A (en) | 1995-12-20 | 1999-02-23 | Yamanouchi Pharma Co Ltd | Arylethersulfonamide derivatives and drug composition containing the same |
US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
US5958905A (en) | 1996-03-26 | 1999-09-28 | Texas Biotechnology Corporation | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin |
WO1997037986A1 (en) | 1996-04-10 | 1997-10-16 | Warner-Lambert Company | Endothelin antagonists with ether-linked groups |
US6043241A (en) | 1996-04-10 | 2000-03-28 | Warner-Lambert Company | Ketoacid endothelin antagonists |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
-
1996
- 1996-04-15 US US08/632,586 patent/US5804585A/en not_active Expired - Fee Related
-
1997
- 1997-04-09 AU AU26641/97A patent/AU2664197A/en not_active Abandoned
- 1997-04-09 EP EP97918564A patent/EP0898571B1/en not_active Expired - Lifetime
- 1997-04-09 AT AT97918564T patent/ATE254619T1/en not_active IP Right Cessation
- 1997-04-09 WO PCT/US1997/005994 patent/WO1997039000A1/en active IP Right Grant
- 1997-04-09 DE DE69726272T patent/DE69726272D1/en not_active Expired - Lifetime
-
1998
- 1998-09-04 US US09/148,643 patent/US6013655A/en not_active Expired - Fee Related
-
1999
- 1999-11-17 US US09/441,643 patent/US6329387B2/en not_active Expired - Fee Related
-
2001
- 2001-06-15 US US09/881,869 patent/US6545014B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994027979A1 (en) * | 1993-05-20 | 1994-12-08 | Immunopharmaceutics, Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
WO2001049289A1 (en) * | 1999-12-31 | 2001-07-12 | Texas Biotechnology Corporation | Pharmaceutical and veterinary uses of endothelin antagonists |
US6686382B2 (en) | 1999-12-31 | 2004-02-03 | Encysive Pharmaceuticals Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US8017781B2 (en) | 2005-11-15 | 2011-09-13 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
US8445681B2 (en) | 2005-11-15 | 2013-05-21 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
US11911372B2 (en) | 2018-06-28 | 2024-02-27 | Ctxt Pty Ltd | Compounds |
US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
US11492346B2 (en) | 2019-06-18 | 2022-11-08 | Pfizer Inc. | Benzisoxazole sulfonamide derivatives |
Also Published As
Publication number | Publication date |
---|---|
US6329387B2 (en) | 2001-12-11 |
EP0898571B1 (en) | 2003-11-19 |
EP0898571A1 (en) | 1999-03-03 |
US6545014B2 (en) | 2003-04-08 |
ATE254619T1 (en) | 2003-12-15 |
US5804585A (en) | 1998-09-08 |
US6013655A (en) | 2000-01-11 |
DE69726272D1 (en) | 2003-12-24 |
US20010014684A1 (en) | 2001-08-16 |
US20020028829A1 (en) | 2002-03-07 |
AU2664197A (en) | 1997-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0898571B1 (en) | Thieno-pyridine sulfonamides, derivatives thereof and related compounds that modulate the activity of endothelin | |
US5591761A (en) | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | |
US5464853A (en) | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | |
US5514691A (en) | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin | |
US6420567B1 (en) | N-heteroaryl aryl-substituted thienyl-furyl-and pyrrolyl-sulfonamides and derviatives thereof that modulate the activity of endothelin | |
US6265428B1 (en) | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin | |
US6458805B2 (en) | Formulation of sulfonamides for treatment of endothelin-mediated disorders | |
US6248767B1 (en) | Formulation of sulfonamides for treatment of endothelin-mediated disorders | |
JP4202649B2 (en) | Sulfonamides and their derivatives that modulate endothelin activity | |
US6030991A (en) | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | |
US5958905A (en) | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin | |
US6541498B2 (en) | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | |
US6376523B1 (en) | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | |
EP1533311B1 (en) | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997918564 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997918564 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97537219 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997918564 Country of ref document: EP |